A new study published in The Journal of Steroid Biochemistry and Molecular Biology analyzed sclerostin – an important messenger in interaction between bone-vascular axis, investigating the effect of cholecalciferol supplementation on vascular function in non-diabetic chronic kidney disease (CKD) stage G3-4 and vitamin D ≤20ng/ml. This was a double blinded, placebo controlled trial in which equal number of patients were randomized to receive either two directly observed oral doses of 300,000 IU of cholecalciferol or matching placebo, at baseline and at 8 weeks. Of the 120 subjects enrolled, 58 in the cholecalciferol group and 59 in the placebo group completed the study. The results revealed that at baseline, serum levels of sclerostin were equivalent in both the groups. In addition, 16 weeks after cholecalciferol supplementation, there was no change in level of sclerostin. Contrastingly, a significant decrease in sclerostin level was noted in the placebo group. Change (Δ) in sclerostin level at 16 weeks correlated negatively with Δ eGFR and positively with Δ uric acid, but not with Δ25(OH) D, Δ iPTH, ΔFGF23, and Δ1,25 (OH)2 D. From the findings, it was concluded that high dose cholecalciferol supplementation did not change sclerostin levels in non-diabetic stage 3-4 CKD patients.